{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:54:56Z","timestamp":1793382896559,"version":"4.5.0"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41582-025-01133-3","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T11:00:51Z","timestamp":1757070051000},"page":"544-555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The changing landscape of primary autoimmune neuropathies"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9850-8504","authenticated-orcid":false,"given":"Marta","family":"Caballero-\u00c1vila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elba","family":"Pascual-Go\u00f1i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinta","family":"Lleix\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1553-2224","authenticated-orcid":false,"given":"Lorena","family":"Mart\u00edn-Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-1018","authenticated-orcid":false,"given":"Roger","family":"Collet-Vidiella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-8264","authenticated-orcid":false,"given":"Luis","family":"Querol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"1133_CR1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","volume":"10","author":"B van den Berg","year":"2014","unstructured":"van den Berg, B. et al. Guillain\u2013Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat. Rev. Neurol. 10, 469\u2013482 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"1133_CR2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/jnnp-2019-320314","volume":"90","author":"HC Lehmann","year":"2019","unstructured":"Lehmann, H. C., Burke, D. & Kuwabara, S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J. Neurol. Neurosurg. Psychiatry 90, 981\u2013987 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1133_CR3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrneurol.2014.117","volume":"10","author":"N Latov","year":"2014","unstructured":"Latov, N. Diagnosis and treatment of chronic acquired demyelinating polyneuropathies. Nat. Rev. Neurol. 10, 435\u2013446 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"1133_CR4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.23794","volume":"73","author":"L Querol","year":"2013","unstructured":"Querol, L. et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann. Neurol. 73, 370\u2013380 (2013).","journal-title":"Ann. Neurol."},{"key":"1133_CR5","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1093\/brain\/aww189","volume":"139","author":"K Doppler","year":"2016","unstructured":"Doppler, K. et al. Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy. Brain 139, 2617\u20132630 (2016).","journal-title":"Brain"},{"key":"1133_CR6","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1093\/brain\/awab014","volume":"144","author":"E Pascual-Go\u00f1i","year":"2021","unstructured":"Pascual-Go\u00f1i, E. et al. Antibodies to the Caspr1\/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. Brain 144, 2617\u20132630 (2021).","journal-title":"Brain"},{"key":"1133_CR7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/WNL.0000000000002418","volume":"86","author":"JJ Devaux","year":"2016","unstructured":"Devaux, J. J. et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 86, 800\u2013807 (2016).","journal-title":"Neurology"},{"key":"1133_CR8","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/brain\/awac418","volume":"146","author":"L Appeltshauser","year":"2023","unstructured":"Appeltshauser, L. et al. Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo\u2013paranodal damage. Brain 146, 1932\u20131949 (2023).","journal-title":"Brain"},{"key":"1133_CR9","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/brain\/awx124","volume":"140","author":"E Delmont","year":"2017","unstructured":"Delmont, E. et al. Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain\u00a0140, 1851\u20131858 (2017).","journal-title":"Brain"},{"key":"1133_CR10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1212\/WNL.0000000000000205","volume":"82","author":"L Querol","year":"2014","unstructured":"Querol, L. et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 82, 879\u2013886 (2014).","journal-title":"Neurology"},{"key":"1133_CR11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/WCO.0000000000001107","volume":"35","author":"L Mart\u00edn-Aguilar","year":"2022","unstructured":"Mart\u00edn-Aguilar, L., Lleix\u00e0, C. & Pascual-Go\u00f1i, E. Autoimmune nodopathies, an emerging diagnostic category. Curr. Opin. Neurol. 35, 579\u2013585 (2022).","journal-title":"Curr. Opin. Neurol."},{"key":"1133_CR12","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","volume":"28","author":"PYZ Van den Bergh","year":"2021","unstructured":"Van den Bergh, P. Y. Z. et al. European Academy of Neurology\/Peripheral Nerve Society Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force\u2014second revision. Eur. J. Neurol. 28, 3556\u20133583 (2021).","journal-title":"Eur. J. Neurol."},{"key":"1133_CR13","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1111\/ene.16073","volume":"30","author":"PA van Doorn","year":"2023","unstructured":"van Doorn, P. A. et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain\u2013Barr\u00e9 syndrome. Eur. J. Neurol. 30, 3646\u20133674 (2023).","journal-title":"Eur. J. Neurol."},{"key":"1133_CR14","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1093\/brain\/awaa265","volume":"143","author":"F Eftimov","year":"2021","unstructured":"Eftimov, F., Lucke, I. M., Querol, L. A., Rajabally, Y. A. & Verhamme, C. Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy. Brain 143, 3214\u20133224 (2021).","journal-title":"Brain"},{"key":"1133_CR15","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/14737175.2021.1944104","volume":"21","author":"JA Allen","year":"2021","unstructured":"Allen, J. A., Eftimov, F. & Querol, L. Outcome measures and biomarkers in chronic inflammatory demyelinating polyradiculoneuropathy: from research to clinical practice. Expert Rev. Neurother. 21, 805\u2013816 (2021).","journal-title":"Expert Rev. Neurother."},{"key":"1133_CR16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410110205","volume":"11","author":"PJ Dyck","year":"1982","unstructured":"Dyck, P. J. et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann. Neurol. 11, 136\u2013141 (1982).","journal-title":"Ann. Neurol."},{"key":"1133_CR17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM198602203140801","volume":"314","author":"Dyck","year":"1986","unstructured":"Dyck et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N. Engl. J. Med. 314, 461\u2013465 (1986).","journal-title":"N. Engl. J. Med."},{"key":"1133_CR18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0022-510X(85)90173-X","volume":"70","author":"M Vermeulen","year":"1985","unstructured":"Vermeulen, M., van der Mech\u00e9, F. G., Speelman, J. D., Weber, A. & Busch, H. F. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J. Neurol. Sci. 70, 317\u2013326 (1985).","journal-title":"J. Neurol. Sci."},{"key":"1133_CR19","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","volume":"326","author":"FG van der Mech\u00e9","year":"1992","unstructured":"van der Mech\u00e9, F. G. & Schmitz, P. I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain\u2013Barr\u00e9 Syndrome. N. Engl. J. Med. 326, 1123\u20131129 (1992).","journal-title":"N. Engl. J. Med."},{"key":"1133_CR20","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","volume":"35","author":"The Guillain\u2013Barr\u00e9 Syndrome Study Group. Plasmapheresis and acute Guillain\u2013Barre syndrome","year":"1985","unstructured":"The Guillain\u2013Barr\u00e9 Syndrome Study Group. Plasmapheresis and acute Guillain\u2013Barre syndrome Neurology 35, 1096\u20131104 (1985).","journal-title":"Neurology"},{"key":"1133_CR21","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0140-6736(84)90819-5","volume":"2","author":"PO Osterman","year":"1984","unstructured":"Osterman, P. O. et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 2, 1296\u20131299 (1984).","journal-title":"Lancet"},{"key":"1133_CR22","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1007\/s13311-021-01117-3","volume":"18","author":"L Querol","year":"2021","unstructured":"Querol, L. & Lleix\u00e0, C. Novel immunological and therapeutic insights in Guillain\u2013Barr\u00e9 syndrome and CIDP. Neurotherapeutics 18, 2222\u20132235 (2021).","journal-title":"Neurotherapeutics"},{"key":"1133_CR23","volume":"8","author":"S Rinaldi","year":"2013","unstructured":"Rinaldi, S. et al. Antibodies to heteromeric glycolipid complexes in Guillain\u2013Barr\u00e9 syndrome. PLoS ONE 8, e82337 (2013).","journal-title":"PLoS ONE"},{"key":"1133_CR24","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-021-02301-0","volume":"18","author":"C Lleix\u00e0","year":"2021","unstructured":"Lleix\u00e0, C. et al. Autoantibody screening in Guillain\u2013Barr\u00e9 syndrome. J. Neuroinflamm. 18, 251 (2021).","journal-title":"J. Neuroinflamm."},{"key":"1133_CR25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ana.410400414","volume":"40","author":"C Hafer-Macko","year":"1996","unstructured":"Hafer-Macko, C. et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann. Neurol. 40, 635\u2013644 (1996).","journal-title":"Ann. Neurol."},{"key":"1133_CR26","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1073\/pnas.0402391101","volume":"101","author":"N Yuki","year":"2004","unstructured":"Yuki, N. et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain\u2013Barr\u00e9 syndrome. Proc. Natl Acad. Sci. USA 101, 11404\u201311409 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1133_CR27","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1086\/513799","volume":"176","author":"HJ Willison","year":"1997","unstructured":"Willison, H. J. et al. Mechanisms of action of anti-GM 1 and anti-GQ 1b ganglioside antibodies in Guillain\u2013Barr\u00e9 syndrome. J. Infect. Dis. 176, S144\u2013S149 (1997).","journal-title":"J. Infect. Dis."},{"key":"1133_CR28","doi-asserted-by":"crossref","first-page":"awaf102","DOI":"10.1093\/brain\/awaf102","volume":"17","author":"RCM Thomma","year":"2025","unstructured":"Thomma, R. C. M. et al. Large-scale profiling of antibody reactivity to glycolipids in 1 patients with Guillain\u2013Barr\u00e9 syndrome. Brain 17, awaf102 (2025).","journal-title":"Brain"},{"key":"1133_CR29","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/jnnp-2012-302824","volume":"84","author":"N Shahrizaila","year":"2013","unstructured":"Shahrizaila, N. & Yuki, N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J. Neurol. Neurosurg. Psychiatry 84, 576\u2013583 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1133_CR30","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ana.410310619","volume":"31","author":"A Chiba","year":"1992","unstructured":"Chiba, A., Kusunoki, S., Shimizu, T. & Kanazawa, I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann. Neurol. 31, 677\u2013679 (1992).","journal-title":"Ann. Neurol."},{"key":"1133_CR31","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000501","volume":"5","author":"K Yoshikawa","year":"2018","unstructured":"Yoshikawa, K. et al. Varied antibody reactivities and clinical relevance in anti-GQ1b antibody-related diseases. Neurol. Neuroimmunol. Neuroinflamm. 5, e501 (2018).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1133_CR32","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200047","volume":"10","author":"AJ Davies","year":"2023","unstructured":"Davies, A. J. et al. Guillain\u2013Barr\u00e9 syndrome following Zika virus infection is associated with a diverse spectrum of peripheral nerve reactive antibodies. Neurol. Neuroimmunol. Neuroinflamm. 10, e200047 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1133_CR33","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.24755","volume":"80","author":"PM Meyer Sauteur","year":"2016","unstructured":"Meyer Sauteur, P. M. et al. Mycoplasma pneumoniae triggering the Guillain\u2013Barr\u00e9 syndrome: a case\u2013control study. Ann. Neurol. 80, 566\u2013580 (2016).","journal-title":"Ann. Neurol."},{"key":"1133_CR34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jneuroim.2016.10.006","volume":"15","author":"M Samukawa","year":"2016","unstructured":"Samukawa, M. et al. Electrophysiological assessment of Guillain\u2013Barr\u00e9 syndrome with both Gal-C and ganglioside antibodies; tendency for demyelinating type. J. Neuroimmunol. 15, 61\u201364 (2016).","journal-title":"J. Neuroimmunol."},{"key":"1133_CR35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06916-6","volume":"626","author":"L S\u00faken\u00edkov\u00e1","year":"2024","unstructured":"S\u00faken\u00edkov\u00e1, L. et al. Autoreactive T cells target peripheral nerves in Guillain\u2013Barr\u00e9 syndrome. Nature 626, 160\u2013168 (2024).","journal-title":"Nature"},{"key":"1133_CR36","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209725","volume":"103","author":"E Pascual-Go\u00f1i","year":"2024","unstructured":"Pascual-Go\u00f1i, E., Caballero-\u00c1vila, M. & Querol, L. Antibodies in autoimmune neuropathies: what to test, how to test, why to test. Neurology 103, e209725 (2024).","journal-title":"Neurology"},{"key":"1133_CR37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/jnnp-2019-321532","volume":"91","author":"WZ Yeh","year":"2020","unstructured":"Yeh, W. Z., Dyck, P. J., Van Den Berg, L. H., Kiernan, M. C. & Taylor, B. V. Multifocal motor neuropathy: controversies and priorities. J. Neurol. Neurosurg. Psychiatry 91, 140\u2013148 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1133_CR38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1468-1331.2012.03767.x","volume":"20","author":"F Galban-Horcajo","year":"2013","unstructured":"Galban-Horcajo, F. et al. Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy. Eur. J. Neurol. 20, 62\u201370 (2013).","journal-title":"Eur. J. Neurol."},{"key":"1133_CR39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/jnr.490250305","volume":"25","author":"LH Van Den Berg","year":"1990","unstructured":"Van Den Berg, L. H., Sadiq, S. A., Thomas, F. P. & Latov, N. Characterization of HNK-1 bearing glycoproteins in human peripheral nerve myelin. J. Neurosci. Res. 25, 295\u2013299 (1990).","journal-title":"J. Neurosci. Res."},{"key":"1133_CR40","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1093\/brain\/124.10.1968","volume":"124","author":"H Willison","year":"2001","unstructured":"Willison, H. et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 124, 1968\u20131977 (2001).","journal-title":"Brain"},{"key":"1133_CR41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ana.24680","volume":"80","author":"O Harschnitz","year":"2016","unstructured":"Harschnitz, O. et al. Autoantibody pathogenicity in a multifocal motor neuropathy induced pluripotent stem cell-derived model. Ann. Neurol. 80, 71\u201388 (2016).","journal-title":"Ann. Neurol."},{"key":"1133_CR42","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrneurol.2011.121","volume":"7","author":"MC Dalakas","year":"2011","unstructured":"Dalakas, M. C. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat. Rev. Neurol. 7, 507\u2013517 (2011).","journal-title":"Nat. Rev. Neurol."},{"key":"1133_CR43","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s13311-022-01221-y","volume":"19","author":"L Querol","year":"2022","unstructured":"Querol, L. et al. The role of the complement system in chronic inflammatory demyelinating polyneuropathy: implications for complement-targeted therapies. Neurotherapeutics 19, 864\u2013873 (2022).","journal-title":"Neurotherapeutics"},{"key":"1133_CR44","volume":"9","author":"L Mart\u00edn-Aguilar","year":"2021","unstructured":"Mart\u00edn-Aguilar, L. et al. Clinical and laboratory features in anti-NF155 autoimmune nodopathy. Neurol. Neuroimmunol. Neuroinflamm. 9, e1098 (2021).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1133_CR45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/ana.27142","volume":"97","author":"M Caballero-\u00c1vila","year":"2025","unstructured":"Caballero-\u00c1vila, M. et al. Long-term follow up in anti-contactin-1 autoimmune nodopathy. Ann. Neurol. 97, 529\u2013541 (2025).","journal-title":"Ann. Neurol."},{"key":"1133_CR46","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/brain\/aww062","volume":"139","author":"C Manso","year":"2016","unstructured":"Manso, C., Querol, L., Mekaouche, M., Illa, I. & Devaux, J. J. Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects. Brain 139, 1700\u20131712 (2016).","journal-title":"Brain"},{"key":"1133_CR47","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1172\/JCI124694","volume":"129","author":"C Manso","year":"2019","unstructured":"Manso, C. et al. Anti-neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo. J. Clin. Invest. 129, 2222\u20132236 (2019).","journal-title":"J. Clin. Invest."},{"key":"1133_CR48","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000639","volume":"7","author":"A Cortese","year":"2020","unstructured":"Cortese, A. et al. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: clinical relevance of IgG isotype. Neurol. Neuroimmunol. Neuroinflamm. 7, e639 (2020).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1133_CR49","doi-asserted-by":"crossref","first-page":"1021513","DOI":"10.3389\/fimmu.2023.1021513","volume":"14","author":"G Taieb","year":"2023","unstructured":"Taieb, G. et al. Effect of monovalency on anti-contactin-1 IgG4. Front. Immunol. 14, 1021513 (2023).","journal-title":"Front. Immunol."},{"key":"1133_CR50","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200014","volume":"9","author":"A Jentzer","year":"2022","unstructured":"Jentzer, A. et al. IgG4 valency modulates the pathogenicity of anti-neurofascin-155 IgG4 in autoimmune nodopathy. Neurol. Neuroimmunol. Neuroinflamm. 9, e200014 (2022).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1133_CR51","doi-asserted-by":"crossref","first-page":"200081","DOI":"10.1212\/NXI.0000000000200081","volume":"10","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. Anti-LGI4 antibody is a novel juxtaparanodal autoantibody for chronic inflammatory demyelinating polyneuropathy. Neurol. Neuroimmunol. Neuroinflamm. 10, 200081 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1133_CR52","doi-asserted-by":"crossref","first-page":"200199","DOI":"10.1212\/NXI.0000000000200199","volume":"11","author":"Y Fukami","year":"2024","unstructured":"Fukami, Y. et al. Autoantibodies against dihydrolipoamide S-acetyltransferase in immune-mediated neuropathies. Neurol. Neuroimmunol. Neuroinflamm. 11, 200199 (2024).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1133_CR53","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200336","volume":"12","author":"A Jentzer","year":"2025","unstructured":"Jentzer, A., El-Bechir, J., Taieb, G. & Devaux, J. J. Autoantibodies against dihydrolipoamide S-acetyltransferase are not associated with immune-mediated neuropathies. Neurol. Neuroimmunol. Neuroinflamm. 12, e200336 (2025).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1133_CR54","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000944","volume":"8","author":"CP Moritz","year":"2021","unstructured":"Moritz, C. P. et al. CIDP antibodies target junction proteins and identify patient subgroups: an autoantigenomic approach. Neurol. Neuroimmunol. Neuroinflamm. 8, e944 (2021).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1133_CR55","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200216","volume":"11","author":"M Caballero-\u00c1vila","year":"2024","unstructured":"Caballero-\u00c1vila, M. et al. Membrane proteome-wide screening of autoantibodies in CIDP using human cell microarray technology. Neurol. Neuroimmunol. Neuroinflamm. 11, e200216 (2024).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1133_CR56","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158524","volume":"132","author":"R McGonigal","year":"2022","unstructured":"McGonigal, R. et al. Schwann cell nodal membrane disruption triggers bystander axonal degeneration in a Guillain\u2013Barr\u00e9 syndrome mouse model. J. Clin. Invest. 132, e158524 (2022).","journal-title":"J. Clin. Invest."},{"key":"1133_CR57","doi-asserted-by":"crossref","first-page":"fcac306","DOI":"10.1093\/braincomms\/fcac306","volume":"4","author":"CI Campbell","year":"2022","unstructured":"Campbell, C. I. et al. Complement inhibition prevents glial nodal membrane injury in a GM1 antibody-mediated mouse model. Brain Commun. 4, fcac306 (2022).","journal-title":"Brain Commun."},{"key":"1133_CR58","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001107","volume":"9","author":"K Budding","year":"2022","unstructured":"Budding, K. et al. Anti-C2 antibody ARGX-117 inhibits complement in a disease model for multifocal motor neuropathy. Neurol. Neuroimmunol. Neuroinflamm. 9, e1107 (2022).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1133_CR59","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000119","volume":"2","author":"L Vlam","year":"2015","unstructured":"Vlam, L. et al. Complement activity is associated with disease severity in multifocal motor neuropathy. Neurol. Neuroimmunol. Neuroinflamm. 2, e119 (2015).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1133_CR60","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/brain\/awg207","volume":"126","author":"J Wanschitz","year":"2003","unstructured":"Wanschitz, J., Maier, H., Lassmann, H., Budka, H. & Berger, T. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain\u2013Barr\u00e9 syndrome. Brain 126, 2034\u20132042 (2003).","journal-title":"Brain"},{"key":"1133_CR61","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1172\/JCI113231","volume":"80","author":"CL Koski","year":"1987","unstructured":"Koski, C. L. et al. Activation of terminal components of complement in patients with Guillain\u2013Barre syndrome and other demyelinating neuropathies. J. Clin. Invest. 80, 1492\u20131497 (1987).","journal-title":"J. Clin. Invest."},{"key":"1133_CR62","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/acn3.331","volume":"3","author":"I Quast","year":"2016","unstructured":"Quast, I., Keller, C. W., Hiepe, F., Tackenberg, B. & L\u00fcnemann, J. D. Terminal complement activation is increased and associated with disease severity in CIDP. Ann. Clin. Transl. Neurol. 3, 730\u2013735 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1133_CR63","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2012-07-441857","volume":"121","author":"Y Nevo","year":"2013","unstructured":"Nevo, Y. et al. CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy. Blood 121, 129\u2013135 (2013).","journal-title":"Blood"},{"key":"1133_CR64","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.0000000000001833","volume":"85","author":"JA Allen","year":"2015","unstructured":"Allen, J. A. & Lewis, R. A. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology 85, 498\u2013504 (2015).","journal-title":"Neurology"},{"key":"1133_CR65","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/ene.14796","volume":"28","author":"MC Broers","year":"2021","unstructured":"Broers, M. C. et al. Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy. Eur. J. Neurol. 28, 2065\u20132073 (2021).","journal-title":"Eur. J. Neurol."},{"key":"1133_CR66","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","volume":"27","author":"AK Asbury","year":"1990","unstructured":"Asbury, A. K. & Cornblath, D. R. Assessment of current diagnostic criteria for Guillain\u2013Barr\u00e9 syndrome. Ann. Neurol. 27, S21\u2013S24 (1990).","journal-title":"Ann. Neurol."},{"key":"1133_CR67","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","volume":"29","author":"JJ Sejvar","year":"2011","unstructured":"Sejvar, J. J. et al. Guillain\u2013Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29, 599\u2013612 (2011).","journal-title":"Vaccine"},{"key":"1133_CR68","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/jnnp-2022-329357","volume":"93","author":"PE Doneddu","year":"2022","unstructured":"Doneddu, P. E. et al. Comparison of the diagnostic accuracy of the 2021 EAN\/PNS and 2010 EFNS\/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. Neurosurg. Psychiatry 93, 1239\u20131246 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1133_CR69","first-page":"1247","volume":"93","author":"YA Rajabally","year":"2022","unstructured":"Rajabally, Y. A., Afzal, S., Loo, L. K. & Goedee, H. S. Application of the 2021 EAN\/PNS criteria for chronic inflammatory demyelinating polyneuropathy. J. Neurol. Neurosurg. Psychiatry 93, 1247\u20131252 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1133_CR70","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/pn-2022-003655","volume":"25","author":"M Kapoor","year":"2025","unstructured":"Kapoor, M., Khoo, A., Lunn, M. P. T., Reddel, S. & Carr, A. S. Immunoglobulin use in neurology: a practical approach. Pract. Neurol. 25, 228 (2025).","journal-title":"Pract. Neurol."},{"key":"1133_CR71","volume":"22","author":"SRM Bus","year":"2021","unstructured":"Bus, S. R. M. et al. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC). Trials 22, 155 (2021).","journal-title":"Trials"},{"issue":"Suppl. 3","key":"1133_CR72","first-page":"S3","volume":"29","author":"I van Doorn","year":"2024","unstructured":"van Doorn, I. et al. Optic trial: intravenous immunoglobulin and intravenous methylprednisolone as induction treatment in CIDP [abstract O436]. J. Peripher. Nerv. Syst. 29 (Suppl. 3), S3\u2013S193 (2024).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"1133_CR73","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/jns.12573","volume":"28","author":"V Bril","year":"2023","unstructured":"Bril, V. et al. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: the ADVANCE-CIDP 1 randomized controlled trial. J. Peripher. Nerv. Syst. 28, 436\u2013449 (2023).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"1133_CR74","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","volume":"17","author":"IN van Schaik","year":"2018","unstructured":"van Schaik, I. N. et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 17, 35\u201346 (2018).","journal-title":"Lancet Neurol."},{"key":"1133_CR75","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000149","volume":"2","author":"L Querol","year":"2015","unstructured":"Querol, L. et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol. Neuroimmunol. Neuroinflamm. 2, e149 (2015).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1133_CR76","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03864185 (2021)."},{"key":"1133_CR77","doi-asserted-by":"crossref","DOI":"10.2196\/17117","volume":"9","author":"S Shimizu","year":"2020","unstructured":"Shimizu, S. et al. Efficacy and safety of rituximab in refractory CIDP with or without IgG4 autoantibodies (RECIPE): protocol for a double-blind, randomized, placebo-controlled clinical trial. JMIR Res. Protoc. 9, e17117 (2020).","journal-title":"JMIR Res. Protoc."},{"key":"1133_CR78","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/jnnp-2023-332844","volume":"95","author":"PE Doneddu","year":"2024","unstructured":"Doneddu, P. E. et al. Prospective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies. J. Neurol. Neurosurg. Psychiatry 95, 838\u2013844 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1133_CR79","first-page":"180","volume":"12","author":"D Yet","year":"2024","unstructured":"Du, Y. et al. Efficacy and safety of combined low-dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Clin. Transl. Neurol. 12, 180\u2013191 (2024).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1133_CR80","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/brain\/awae400","volume":"148","author":"E Nobile-Orazio","year":"2025","unstructured":"Nobile-Orazio, E. et al. Rituximab versus placebo for chronic inflammatory 2 demyelinating polyradiculoneuropathy: a randomized trial. Brain 148, 1112\u20131121 (2025).","journal-title":"Brain"},{"key":"1133_CR81","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","volume":"80","author":"JM L\u00e9ger","year":"2013","unstructured":"L\u00e9ger, J. M. et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 80, 2217\u20132225 (2013).","journal-title":"Neurology"},{"key":"1133_CR82","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jns.2017.04.016","volume":"377","author":"MC Dalakas","year":"2017","unstructured":"Dalakas, M. C. Rituximab in anti-MAG neuropathy: more evidence for efficacy and more predictive factors. J. Neurol. Sci. 377, 224\u2013226 (2017).","journal-title":"J. Neurol. Sci."},{"key":"1133_CR83","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1172\/JCI58743","volume":"122","author":"MA Maurer","year":"2012","unstructured":"Maurer, M. A. et al. Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. J. Clin. Invest. 122, 1393\u20131402 (2012).","journal-title":"J. Clin. Invest."},{"key":"1133_CR84","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200122","volume":"10","author":"F Castellani","year":"2023","unstructured":"Castellani, F. et al. Mutational profile in 75 patients with anti-myelin-associated glycoprotein neuropathy: clinical and hematologic therapy response and hints on new therapeutic targets. Neurol. Neuroimmunol. Neuroinflamm. 10, e200122 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1133_CR85","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1506192","volume":"373","author":"SP Treon","year":"2015","unstructured":"Treon, S. P., Xu, L. & Hunter, Z. MYD88 mutations and response to ibrutinib in Waldenstr\u00f6m\u2019s macroglobulinemia. N. Eng. J. Med. 373, 584\u2013586 (2015).","journal-title":"N. Eng. J. Med."},{"key":"1133_CR86","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000720","volume":"7","author":"F Castellani","year":"2020","unstructured":"Castellani, F. et al. The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. Neurol. Neuroimmunol. Neuroinflamm. 7, e720 (2020).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1133_CR87","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/bloodadvances.2024014115","volume":"9","author":"B Heyman","year":"2025","unstructured":"Heyman, B., Tam Alfred, C., Buske, C. & St Owen, J. R. Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenstr\u00f6m macroglobulinemia. Blood Adv. 9, 722\u2013728 (2025).","journal-title":"Blood Adv."},{"key":"1133_CR88","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05939037 (2025)."},{"key":"1133_CR89","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05065554 (2025)."},{"key":"1133_CR90","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","volume":"146","author":"DD Patel","year":"2020","unstructured":"Patel, D. D. & Bussel, J. B. Neonatal Fc receptor in human immunity: function and role in therapeutic intervention. J. Allergy Clin. Immunol. 146, 467\u2013478 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1133_CR91","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13311-021-01175-7","volume":"19","author":"C Nelke","year":"2022","unstructured":"Nelke, C., Spatola, M., Schroeter, C. B., Wiendl, H. & L\u00fcnemann, J. D. Neonatal Fc receptor-targeted therapies in neurology. Neurotherapeutics 19, 729\u2013740 (2022).","journal-title":"Neurotherapeutics"},{"key":"1133_CR92","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JFJr Howard","year":"2021","unstructured":"Howard, J. F. Jr et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 20, 526\u2013536 (2021).","journal-title":"Lancet Neurol."},{"key":"1133_CR93","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/1531-8249(200006)47:6<765::AID-ANA9>3.0.CO;2-8","volume":"47","author":"WX Yan","year":"2000","unstructured":"Yan, W. X., Taylor, J., Andrias-Kauba, S. & Pollard, J. D. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann. Neurol. 47, 765\u2013775 (2000).","journal-title":"Ann. Neurol."},{"key":"1133_CR94","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/brain\/awg030","volume":"126","author":"MSG Kwa","year":"2003","unstructured":"Kwa, M. S. G. et al. Autoimmunoreactivity to Schwann cells in patients with inflammatory neuropathies. Brain 126, 361\u2013375 (2003).","journal-title":"Brain"},{"key":"1133_CR95","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14853-4","volume":"7","author":"L Querol","year":"2017","unstructured":"Querol, L. et al. Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. Sci. Rep. 7, 14411 (2017).","journal-title":"Sci. Rep."},{"key":"1133_CR96","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts, P. et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J. Clin. Invest. 128, 4372\u20134386 (2018).","journal-title":"J. Clin. Invest."},{"key":"1133_CR97","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","volume":"23","author":"JA Allen","year":"2023","unstructured":"Allen, J. A. et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 23, 1013\u20131024 (2023).","journal-title":"Lancet Neurol."},{"key":"1133_CR98","unstructured":"Vyvgart: Efgartigimod alfa. European Medicines Agency https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vyvgart."},{"key":"1133_CR99","unstructured":"FDA approves treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. UA Food and Drug Administration https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-chronic-inflammatory-demyelinating-polyneuropathy-cidp-adults (2024)."},{"key":"1133_CR100","first-page":"1111","volume":"7","author":"B Smith","year":"2018","unstructured":"Smith, B. et al. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. mAbs 7, 1111\u20131130 (2018).","journal-title":"mAbs"},{"key":"1133_CR101","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/jnnp-2023-333112","volume":"95","author":"L Querol","year":"2024","unstructured":"Querol, L. et al. Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study. J. Neurol. Neurosurg. Psychiatry 95, 845\u2013854 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1133_CR102","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","volume":"105","author":"LE Ling","year":"2019","unstructured":"Ling, L. E. et al. M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study. Clin. Pharmacol. Ther. 105, 1031\u20131039 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1133_CR103","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05581199 (2024)."},{"key":"1133_CR104","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05327114 (2025)."},{"key":"1133_CR105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41582-024-01045-8","volume":"21","author":"JD L\u00fcnemann","year":"2025","unstructured":"L\u00fcnemann, J. D. Moving beyond immunoglobulin therapy for CIDP with efgartigimod. Nat. Rev. Neurol. 21, 1\u20132 (2025).","journal-title":"Nat. Rev. Neurol."},{"key":"1133_CR106","doi-asserted-by":"crossref","first-page":"123355","DOI":"10.1016\/j.jns.2024.123355","volume":"468","author":"J Katz","year":"2025","unstructured":"Katz, J., Jenkins, L. & Saperstein, D. Unresolved issues with efgartigimod in CIDP, and broader concerns for future trial design. J. Neurol. Sci. 468, 123355 (2025).","journal-title":"J. Neurol. Sci."},{"key":"1133_CR107","doi-asserted-by":"crossref","first-page":"123313","DOI":"10.1016\/j.jns.2024.123313","volume":"468","author":"T Levine","year":"2025","unstructured":"Levine, T. & Muley, S. Early deterioration of CIDP following transition from IVIG to FcRn inhibitor treatment. J. Neurol. Sci. 468, 123313 (2025).","journal-title":"J. Neurol. Sci."},{"key":"1133_CR108","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s40265-020-01418-5","volume":"80","author":"ZT Al-Salama","year":"2020","unstructured":"Al-Salama, Z. T. Imlifidase: first approval. Drugs 80, 1859\u20131864 (2020).","journal-title":"Drugs"},{"key":"1133_CR109","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/ajt.16828","volume":"22","author":"E Huang","year":"2022","unstructured":"Huang, E., Maldonado, A. Q., Kjellman, C. & Jordan, S. C. Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation. Am. J. Transplant. 22, 691\u2013697 (2022).","journal-title":"Am. J. Transplant."},{"key":"1133_CR110","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03943589 (2025)."},{"issue":"Suppl. 3","key":"1133_CR111","first-page":"S3","volume":"30","author":"S Attarian","year":"2025","unstructured":"Attarian, S. et al. Outcomes in patients with severe Guillain\u2013Barr\u00e9 syndrome treated with imlifidase and standard-of-care immunoglobulin [abstract O582]. J. Peripher. Nerv. Syst. 30 (Suppl. 3), S3\u2013S263 (2025).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"1133_CR112","doi-asserted-by":"crossref","first-page":"104134","DOI":"10.1016\/j.drudis.2024.104134","volume":"29","author":"HB Bouwman","year":"2024","unstructured":"Bouwman, H. B. & Guchelaar, H. J. The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms. Drug Discov. Today 29, 104134 (2024).","journal-title":"Drug Discov. Today"},{"key":"1133_CR113","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","volume":"17","author":"S Misawa","year":"2018","unstructured":"Misawa, S. et al. Safety and efficacy of eculizumab in Guillain\u2013Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 17, 519\u2013529 (2018).","journal-title":"Lancet Neurol."},{"key":"1133_CR114","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/jns.12646","volume":"29","author":"S Kuwabara","year":"2024","unstructured":"Kuwabara, S. et al. Efficacy and safety of eculizumab in Guillain\u2013Barr\u00e9 syndrome: a phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial. J. Peripher. Nerv. Syst. 29, 339\u2013349 (2024).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"1133_CR115","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05494619 (2022)."},{"key":"1133_CR116","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","volume":"11","author":"D Ricklin","year":"2010","unstructured":"Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785\u2013797 (2010).","journal-title":"Nat. Immunol."},{"key":"1133_CR117","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","volume":"16","author":"MC Dalakas","year":"2020","unstructured":"Dalakas, M. C., Alexopoulos, H. & Spaeth, P. J. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat. Rev. Neurol. 16, 601\u2013617 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"1133_CR118","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/1091581817740873","volume":"36","author":"JA Lansita","year":"2017","unstructured":"Lansita, J. A. et al. Nonclinical development of ANX005: a humanized anti-C1q antibody for treatment of autoimmune and neurodegenerative diseases. Int. J. Toxicol. 36, 449\u2013462 (2017).","journal-title":"Int. J. Toxicol."},{"key":"1133_CR119","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04701164 (2025)."},{"key":"1133_CR120","doi-asserted-by":"crossref","DOI":"10.1111\/jns.70009","volume":"30","author":"QD Mohammad","year":"2025","unstructured":"Mohammad, Q. D. et al. Results from a phase 1 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ANX005, a C1q inhibitor, in patients with Guillain\u2013Barr\u00e9 syndrome. J. Peripher. Nerv. Syst. 30, e70009 (2025).","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"Suppl. 3","key":"1133_CR121","first-page":"S3","volume":"29","author":"H-A Kroon","year":"2024","unstructured":"Kroon, H.-A. et al. Design of a phase 3 study evaluating ANX005 in patients with Guillain\u2013Barr\u00e9 syndrome [abstract O 442]. J. Peripher. Nerv. Syst. 29 (Suppl. 3), S3\u2013S193 (2024).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"1133_CR122","unstructured":"Annexon Biosciences. Topline results from phase 3 study of ANX005 in Guillain\u2013Barr\u00e9 syndrome. https:\/\/ir.annexonbio.com\/static-files\/47fa586f-e9e3-438e-b87c-f9688de7c5f0 (2024)."},{"key":"1133_CR123","unstructured":"Annexon Biosciences. Positive topline data from real-world evidence in Guillain\u2013Barr\u00e9 syndrome. https:\/\/ir.annexonbio.com\/static-files\/3870e9bb-e581-457d-bf6a-84c13ae6ccae (2024)."},{"key":"1133_CR124","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/jns.12551","volume":"28","author":"L Querol","year":"2023","unstructured":"Querol, L. et al. An innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy. J. Peripher. Nerv. Syst. 28, 276\u2013285 (2023).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"1133_CR125","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04658472 (2024)."},{"issue":"Suppl. 3","key":"1133_CR126","first-page":"S3","volume":"29","author":"L Querol","year":"2024","unstructured":"Querol, L. et al. Phase 2 efficacy and safety of riliprubart, a C1s-complement inhibitor, in chronic inflammatory demyelinating polyneuropathy [abstract O 429]. J. Peripher. Nerv. Syst. 29 (Suppl. 3), S3\u2013S193 (2024).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"1133_CR127","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06290141 (2025)."},{"key":"1133_CR128","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06290128 (2025)."},{"key":"1133_CR129","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06920004 (2025)."},{"key":"1133_CR130","volume":"9","author":"K Budding","year":"2021","unstructured":"Budding, K. et al. Anti-C2 antibody ARGX-117 inhibits complement in a disease model for multifocal motor neuropathy. Neurol. Neuroimmunol. Neuroinflamm. 9, e1107 (2021).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1133_CR131","unstructured":"Bardhan, M. & Kaushik, R. StatPearls (StatPearls, 2023)."},{"key":"1133_CR132","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05225675 (2024)."},{"issue":"Suppl. 3","key":"1133_CR133","first-page":"S3","volume":"30","author":"L Querol","year":"2025","unstructured":"Querol, L. et al. Empasiprubart in multifocal motor neuropathy: safety and efficacy data from the phase 2 ARDA study [abstract P420]. J. Peripher. Nerv. Syst. 30 (Suppl. 3), S3\u2013S263 (2025).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"1133_CR134","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06742190 (2025)."},{"key":"1133_CR135","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s00415-019-09367-0","volume":"266","author":"E Delmont","year":"2019","unstructured":"Delmont, E. et al. Relevance of anti-HNK1 antibodies in the management of anti-MAG neuropathies. J. Neurol. 266, 1973\u20131979 (2019).","journal-title":"J. Neurol."},{"key":"1133_CR136","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/jns.12565","volume":"28","author":"L Bresciani","year":"2023","unstructured":"Bresciani, L. et al. Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: potential relevance of antibody titers in monitoring treatment response. J. Peripher. Nerv. Syst. 28, 522\u2013527 (2023).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"1133_CR137","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","volume":"20","author":"M Khalil","year":"2024","unstructured":"Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders \u2014 towards clinical application. Nat. Rev. Neurol. 20, 269\u2013287 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"1133_CR138","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1212\/01.wnl.0000237334.69665.92","volume":"67","author":"A Petzold","year":"2006","unstructured":"Petzold, A. et al. CSF neurofilament levels: a potential prognostic marker in Guillain\u2013Barr\u00e9 syndrome. Neurology 67, 1071\u20131073 (2006).","journal-title":"Neurology"},{"key":"1133_CR139","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/mus.23752","volume":"48","author":"I Dujmovic","year":"2013","unstructured":"Dujmovic, I., Lunn, M. P., Reilly, M. M. & Petzold, A. Serial cerebrospinal fluid neurofilament heavy chain levels in severe Guillain\u2013Barr\u00e9 syndrome. Muscle Nerve 48, 132\u2013134 (2013).","journal-title":"Muscle Nerve"},{"key":"1133_CR140","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp-2020-323899","volume":"92","author":"L Mart\u00edn-Aguilar","year":"2021","unstructured":"Mart\u00edn-Aguilar, L. et al. Serum neurofilament light chain predicts long-term prognosis in Guillain\u2013Barr\u00e9 syndrome patients. J. Neurol. Neurosurg. Psychiatry 92, 70\u201377 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1133_CR141","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-020-01737-0","volume":"17","author":"P Altmann","year":"2020","unstructured":"Altmann, P. et al. Increased serum neurofilament light chain concentration indicates poor outcome in Guillain\u2013Barr\u00e9 syndrome. J. Neuroinflamm.17, 86 (2020).","journal-title":"J. Neuroinflamm."},{"key":"1133_CR142","doi-asserted-by":"crossref","first-page":"105072","DOI":"10.1016\/j.ebiom.2024.105072","volume":"102","author":"SJ Van Tilburg","year":"2024","unstructured":"Van Tilburg, S. J. et al. Dynamics and prognostic value of serum neurofilament light chain in Guillain\u2013Barr\u00e9 syndrome. eBioMedicine 102, 105072 (2024).","journal-title":"eBioMedicine"},{"key":"1133_CR143","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/brain\/awac418","volume":"146","author":"L Appeltshauser","year":"2023","unstructured":"Appeltshauser, L. et al. Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo\u2013paranodal damage 2. Brain 146, 1932\u20131949 (2023).","journal-title":"Brain"},{"key":"1133_CR144","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jns.12319","volume":"24","author":"GGA van Lieverloo","year":"2019","unstructured":"van Lieverloo, G. G. A. et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J. Peripher. Nerv. Syst. 24, 187\u2013194 (2019).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"1133_CR145","doi-asserted-by":"crossref","first-page":"fcab018","DOI":"10.1093\/braincomms\/fcab018","volume":"3","author":"J Godelaine","year":"2021","unstructured":"Godelaine, J. et al. Prognostic value of neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Brain Commun. 3, fcab018 (2021).","journal-title":"Brain Commun."},{"key":"1133_CR146","doi-asserted-by":"crossref","first-page":"123397","DOI":"10.1016\/j.jns.2025.123397","volume":"470","author":"A Llaurad\u00f3","year":"2025","unstructured":"Llaurad\u00f3, A. et al. Usefulness of serum neurofilament light chain in chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. Sci. 470, 123397 (2025).","journal-title":"J. Neurol. Sci."},{"key":"1133_CR147","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/jns.70047","volume":"30","author":"L Querol","year":"2025","unstructured":"Querol, L. et al. Exploratory biomarker analyses in a phase 2 trial of riliprubart for chronic inflammatory demyelinating polyneuropathy.  J. Peripher. Nerv. Syst. 30, S3\u2013S263 (2025).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"1133_CR148","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/mus.28054","volume":"69","author":"VEA Kleinveld","year":"2024","unstructured":"Kleinveld, V. E. A. et al. Multifocal motor neuropathy as a mimic of amyotrophic lateral sclerosis: serum neurofilament light chain as a reliable diagnostic biomarker. Muscle Nerve 69, 422\u2013427 (2024).","journal-title":"Muscle Nerve"},{"key":"1133_CR149","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1007\/s00415-024-12355-8","volume":"271","author":"C Wohnrade","year":"2024","unstructured":"Wohnrade, C. et al. Diagnostic value of neurofilaments in differentiating motor neuron disease from multifocal motor neuropathy. J. Neurol. 271, 4441\u20134452 (2024).","journal-title":"J. Neurol."},{"key":"1133_CR150","doi-asserted-by":"crossref","unstructured":"Sheth, U. et al. Measuring neurofilament light in human plasma and cerebrospinal fluid: a comparison of five analytical immunoassays. Preprint at bioRxiv 05.05.652212 (2025).","DOI":"10.1101\/2025.05.05.652212"},{"key":"1133_CR151","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1007\/s00415-022-10993-4","volume":"269","author":"Ket Amaador","year":"2022","unstructured":"Amaador, K. et al. Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy. J. Neurol. 269, 3700\u20133705 (2022).","journal-title":"J. Neurol."},{"issue":"Suppl. 3","key":"1133_CR152","first-page":"S3","volume":"29","author":"E Pascual-Go\u00f1i","year":"2024","unstructured":"Pascual-Go\u00f1i, E. et al. Anti-HNK-1 IgM and sNfL levels are potential biomarkers for monitoring disease activity in anti-MAG neuropathy. [abstract P264]. J. Peripher. Nerv. Syst. 29 (Suppl. 3), S3\u2013S193 (2024).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"1133_CR153","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1093\/brain\/awad234","volume":"146","author":"S Keddie","year":"2023","unstructured":"Keddie, S. et al. Peripherin is a biomarker of axonal damage in peripheral nervous system disease. Brain 146, 4562\u20134573 (2023).","journal-title":"Brain"},{"key":"1133_CR154","doi-asserted-by":"publisher","unstructured":"Bellanti, R. et al. Plasma periaxin is a biomarker of peripheral nerve demyelination. Brain https:\/\/doi.org\/10.1093\/brain\/awaf234 (2025).","DOI":"10.1093\/brain\/awaf234"},{"key":"1133_CR155","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/jnnp-2023-332398","volume":"95","author":"L Wieske","year":"2024","unstructured":"Wieske, L. et al. Proximity extension assay-based discovery of biomarkers for disease activity in chronic inflammatory demyelinating polyneuropathy. J. Neurol. Neurosurg. Psychiatry 95, 595\u2013604 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01133-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01133-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01133-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T12:02:52Z","timestamp":1759147372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01133-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":155,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1133"],"URL":"https:\/\/doi.org\/10.1038\/s41582-025-01133-3","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"14 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.Q. has received research grants from ArgenX, speaker or expert testimony honoraria from Alnylam, Annexon, ArgenX, Avilar Therapeutics, Biocryst, CSL Behring, Dianthus, LFB, Lycia Therapeutics, Merck, Montis, Novartis, Nuvig Therapeutics, Sanofi-Genzyme and Takeda, serves on Clinical Trial Steering Committees for ArgenX, Sanofi-Genzyme and Takeda and is Principal Investigator of trials for UCB (CIDP01 trial) and Sanofi-Genzyme (Mobilize and Vitalize trials). All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}